Sort
40,608 grants matching “prostate cancer”
Small Molecule PSMA-Targeted Alpha Therapy
$389,581Martin G Pomper · Johns Hopkins University · R01 · FY2021 · CA
Towards Understanding Prostate Cancer Heterogeneity
$389,543Mark A. Rubin · Weill Medical Coll Of Cornell Univ · R01 · FY2007 · CA
TOPIC 455: IDEAL AT-HOME PROSTATE SPECIFIC ANTIGEN (PSA) TESTING
$389,535Eric Ervin · Electronic Biosciences, Inc. · N43 · FY2024 · CA
Interleukin-1beta and AR-negative tumor cells in metastatic castrate-resistant prostate cancer
$389,523Alessandro Fatatis · Drexel University · R01 · FY2022 · CA
Prostatectomy vs watchful waiting - a randomized trial.
$389,464Gunnar Steineck · Karolinska Institute · R01 · FY2006 · CA
Genetic and Molecular Basis of Rapamycin Sensitivity
$389,448Washington University · R01 · FY2003 · CA
Breast and Prostate Cancer Patterns of Care in Kentucky
$389,442Steven Thomas Fleming · University Of Kentucky · U01 · FY2006 · DP
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.
$389,441Dominic James Smiraglia · Roswell Park Cancer Institute Corp · R01 · FY2017 · CA
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.
$389,441Dominic James Smiraglia · Roswell Park Cancer Institute Corp · R01 · FY2018 · CA
HCS to Identify Inhibitors and Disruptors of AR-TIF2 Interactions
$389,435Paul A. Johnston · University Of Pittsburgh At Pittsburgh · R01 · FY2015 · CA
Community Outreach & Engagement
$389,433Jason A Mendoza · Fred Hutchinson Cancer Research Center · P30 · FY2021 · CA
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.
$389,422Dominic James Smiraglia · Roswell Park Cancer Institute Corp · R01 · FY2016 · CA
MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES
$389,386Craig Lee Slingluff · University Of Virginia · U01 · FY2014 · CA
Understanding the full spectrum of epigenetic vulnerability in cancer through the delineation of DNA methylation function in gene 3' end
$389,313Angela H Ting · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · CA
Project 1: Tumor Microenvironment Initiators of the Metastatic Cascade in High-Risk Prostate Cancer
$389,239Joshua Michael Lang · University Of Wisconsin-Madison · P50 · FY2024 · CA
Prostatitis and Prostate Cancer Development
$389,187Lawrence Fong · University Of California, San Francisco · R01 · FY2013 · CA
Development of peptide antagonists of estrogen signaling
$389,184Duke University · R01 · FY2003 · CA
The role of MnSOD allelic variations in prostate cancer etiology and outcome
$389,176Alan Diamond · University Of Illinois At Chicago · R01 · FY2016 · CA
Development of Castration Resistance by Alternative AR Splicing
$389,164Stephen R Plymate · Beth Israel Deaconess Medical Center · P01 · FY2017 · CA
Assessing the Value of Aggressive Treatment of Low-Risk Prostate Cancer
$389,134Jean M Mitchell · Georgetown University · R01 · FY2018 · HS
Ex vivo culture platform validation for preservation of patient derived multiple myeloma cells
$389,121Jenny Zilberberg · Hackensack University Medical Center · R33 · FY2018 · CA
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers
$389,092Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2023 · CA
Development of Castration Resistance by Alternative AR Splicing
$389,080Stephen R Plymate · Beth Israel Deaconess Medical Center · P01 · FY2016 · CA
PSYCHOSTIMULANTS FOR FATIGUE IN AMBULATORY MEN WITH PC
$389,068Sloan-Kettering Institute For Cancer Res · R01 · FY2002 · CA
Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancer
$388,990Li Jia · Brigham And Women'S Hospital · R01 · FY2024 · CA